Nirsevimab RSV Raises Infant Mortality Concerns
Respiratory syncytial virus (RSV) is a common viral infection affecting infants (~3.6 million total population) mainly under age 1 year easily treated with nebulizer therapy.
Urgent care, emergency room, and hospitalization can occur for serious cases and if treated early, infant mortality should not be a concern.
Among the 22.4 million children under age 5 years, the annual risk of RSV hospitalization is well under one percent.
The CDC estimates 100-300 RSV deaths per year under age 5 years. Likely most would be avoided with early albuterol/budesonide nebulization therapy at home.
The Bio-Pharmaceutical Complex has targeted RSV as we emerge from the pandemic as a viral threat to propagandize young parents in an all-out war against the virus.
Incredibly there are prefusion antigen vaccines for pregnant mothers and adults who do not have significant risks for the disease and now Nirsevimab (Beyfortis, Sanofi, AstraZeneca) monoclonal antibodies are widely endorsed and given on the first day of life in the US since October, 2023, with no long-term safety data.
I sat down for this breaking interview with Dr. Helene Banoun, former INSERM (Paris, Île-de-France) scientist and now independent researcher in France. Please listen carefully to her analysis. She has a concern about antibody-dependent enhancement of RSV in the original RCTs and the ~200,000 babies in France who have been injected since September 15, 2023.
This means as ambient aerosolized RSV virions are present in hospitals, clinics, and home, the monoclonal antibody may backfire and enable the inhaled virion to gain access to the bronchial epithelial lining and cause worse bronchiolitis than the baby would have with their own developing natural immunity.
This would explain why the efficacy for RSV hospitalization was NOT compelling from the two RCTs of Nirsevimab (Griffin et al, NEJM 2020, and Hammitt et al [MELODY Trial], NEJM, 2020).
In France, according to Banoun, Sanofi is directly financially incentivizing hospitals and midwives to give the injection. Corruption is wide open.
Banoun, while calling for EMA investigation of the deaths, is being heavily censored including complete shadow-bans and inability to stream videos from her home computer IP address over her internet provider Orange Internet.
If you are a young parent or grandparent, you must listen to this interview to get this breaking information about Nirsevimab.
Dr. Banoun indicated that she would advise against this novel product.
Newborns have never been given a monoclonal antibody on the day of birth ever in the history of mankind and like with the COVID-19 vaccines, the Bio-Pharmaceutical Complex is running the table prioritizing profits by risking the lives of newborns.
See more here substack.com
Header image: University of Oxford
Please Donate Below To Support Our Ongoing Work To Defend The Scientific Method
PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company 
incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX.
Trackback from your site.
Anapat
| #
During 2020-2022 WHO refused monoclonal antibodies to people who were dying of pneumonia rebranded Covid. They only made this treatment available on February 11, 2022. And now they inject monoclonal antibodies into babies for “prevention” purpose. Modern medecine is really really going haywire.
Reply